Patents by Inventor Mingwei Zheng

Mingwei Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof
    Patent number: 11787766
    Abstract: Provided are a compound for the prevention and treatment of diseases associated with PD-L1, a preparation method therefor and use thereof. Specifically, provided are the compound of formula I, the stereoisomer and the racemate thereof, or pharmaceutically acceptable salts thereof, and also provided is an application thereof in the preparation of a drug for the prevention and treatment of diseases associated with PD-L1.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: October 17, 2023
    Assignee: SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD.
    Inventors: Lei Jiang, Jianwen Deng, Xiaoli Lu, Ke Shang, Jianyong Shou, Bing Wang, Danyi Wu, Xueli Xu, Yuan Xu, Yi Zhang, Mingwei Zheng
  • Thyroid hormone receptor agonists and use thereof
    Patent number: 11780825
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 10, 2023
    Assignee: Eccogene (Shanghai) Co., Ltd.
    Inventors: Jingye Zhou, Jiuxiang Zhu, Mingwei Zheng
  • AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY
    Publication number: 20210371415
    Abstract: Provided are a JAK kinase inhibitor, preparation and use thereof. In particular, provided is a compound of Formula I, wherein each group is as described in the specification. The compound has an excellent JAK inhibitory activity, and therefore can be used to prepare pharmaceutical compositions for the treatment of cancer and other diseases related to JAK activity.
    Type: Application
    Filed: September 23, 2019
    Publication date: December 2, 2021
    Inventors: Lei JIANG, Jianwen DENG, Zhiyong FENG, Shengyang LIU, Xudong MAO, Ke SHANG, Jianyong SHOU, Danyi WU, Xiaoping XIE, Yuan XU, Haixia ZHAO, Jianhua ZHANG, Mingwei ZHENG
  • THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF
    Publication number: 20210230146
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.
    Type: Application
    Filed: January 13, 2021
    Publication date: July 29, 2021
    Inventors: Jingye ZHOU, Jiuxiang ZHU, Mingwei ZHENG
  • COMPOUND HAVING PD-L1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20200392083
    Abstract: Provided are a compound for the prevention and treatment of diseases associated with PD-L1, a preparation method therefor and use thereof. Specifically, provided are the compound of formula I, the stereoisomer and the racemate thereof, or pharmaceutically acceptable salts thereof, and also provided is an application thereof in the preparation of a drug for the prevention and treatment of diseases associated with PD-Ll.
    Type: Application
    Filed: August 17, 2018
    Publication date: December 17, 2020
    Inventors: Lei JIANG, Jianwen DENG, Xiaoli LU, Ke SHANG, Jianyong SHOU, Bing WANG, Danyi WU, Xueli XU, Yuan XU, Yi ZHANG, Mingwei ZHENG
  • Inhibitors of hepatitis C virus replication
    Patent number: 9090661
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: July 28, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, John A. McCauley, Steven W. Ludmerer, Kun Liu, Joseph P. Vacca, Hao Wu, Bin Hu, Richard Soll, Fei Sun, Xinghai Wang, Man Yan, Chengren Zhang, Mingwei Zheng, Bin Zhong, Jian Zhu
  • INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20140371138
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, John A. McCauley, Steven W. Ludmerer, Kun Liu, Joseph P. Vacca, Hao Wu, Bin Hu, Richard Soll, Fei Sun, Xinghai Wang, Man Yan, Chengren Zhang, Mingwei Zheng, Bin Zhong, Jian Zhu
  • INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20120083483
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Application
    Filed: March 25, 2010
    Publication date: April 5, 2012
    Applicant: Merck Sharp & Dohme Corp
    Inventors: Craig A. Coburn, John A. McCauley, Steven W. Ludmerer, Kun Liu, Joseph P. Vacca, Hao Wu, Bin Hu, Richard Soll, Fei Sun, Xinghai Wang, Man Yan, Chengren Zhang, Mingwei Zheng, Bin Zhong, Jian Zhu